soul trial oral semaglutide cardiovascular outcomes 2025 results in High- Risk Type 2 Diabetes: Benefit Confirmed in the SOUL Trial Shows Oral Semaglutide – New Science Suggests Semaglutide Improves

Mucosal immune system and M cell-targeting strategies for oral mucosal vaccination

Research published in Molecular Medicine found KPV reduced colitis severity scores by 4060% and improved intestinal permeability by 35% in preclinical models

The trial included over 3,400 people with a BMI of 30 or above (or 27+ with at least one weight-related health condition) and without type 2 diabetes

Ozempic is semaglutide, the active ingredient in that FDA-approved GLP-1 receptor agonist for type 2 diabetes, and GLP-1 promotes satiety and helps regulate blood sugar

doi: 10.1038/s41575-022-00631-9 13 CentanniM.BenvengaS.SachmechiI

Real Peptides produces research-grade MT-2 under GMP-compliant conditions, but it is supplied for research purposes, not clinical use